Merck an Unhealthy Stock to Sell

By
A A A

Merck & Co. (NYSE: MRK ) - Following a major advance in the stock market, investors should review their holdings and cull out non-performers that are inhibiting overall portfolio profits. Despite being a global health care company, MRK is one of those stocks to sell.

Not only is the stock still in a bear trend, but the past five years have averaged a negative earnings growth of about 33%, and current profit margins are at a mere 1.87% in an industry that averages in the teens.

About a month ago, TD Ameritrade cut their opinion of MRK to "reduce," and we agree. Even though the dividend yield is at 4.7%, there is no assurance that it will stay at that level, and an increase in bond interest rates would bring in sellers who have held this stock as a "bond substitute."

Sell MRK at the market.

Trade of the Day - Merck & Co. (NYSE: MRK) Chart

Trade of the Day Chart Key

If you have questions or comments for Sam Collins, please e-mail him at samailc@cox.net .



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: Investing , Stocks

Referenced Stocks: MRK

Sam Collins

Sam Collins

More from Sam Collins:

Related Videos

Stocks

Referenced

82%

Most Active by Volume

74,282,785
  • $10.84 ▲ 11.64%
60,794,128
  • $17.12 ▲ 0.71%
55,628,662
  • $35.59 ▼ 1.00%
55,306,290
  • $116.47 ▲ 0.14%
55,118,241
  • $39.75 ▼ 0.43%
53,597,648
  • $9.41 ▲ 8.29%
41,889,990
  • $47.98 ▼ 1.48%
35,692,375
  • $97.34 ▼ 0.57%
As of 11/21/2014, 04:15 PM

Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com